自免药物在国内的热度,已经被康诺亚的司普奇拜单抗带起来了。司普奇拜单抗在去年9月获批了第一个适应症—特应性皮炎 ,随之很快就拿下了慢性鼻窦炎伴鼻息肉、季节性过敏性鼻炎两个鼻科适应症,成为国内首个批准用于治疗慢性鼻窦炎伴鼻息肉的生物制剂、全球唯一治疗季节性过敏性鼻炎的IL-4Rα生物制剂。过去,国内上市的自免药物治疗领域大多在类风湿关节炎、银屑病等几项疾病上,研发扎堆,外界对自免药物的感受也不强。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.